CGC Canopy Growth Corp
Medicinal Chemicals & Botanical Products · Nasdaq · SEC CIK 1737927 · Reporting currency CAD · Fiscal year ends 03/31
Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY10.7%
TTM net income YoY21.3%
TTM EPS YoY66.5%
Revenue 3-yr CAGR1.0%
Net income 3-yr CAGR—
Margins
Gross margin24.4%
Operating margin-54.2%
Net margin-87.8%
FCF margin-25.8%
EBITDA margin-47.5%
Returns
ROE-39.5%
ROA-25.4%
ROIC (approx.)-20.3%
Asset turnover0.29x
Leverage & solvency
Liabilities / assets38.5%
Debt / equity0.38x
Current ratio2.82x
Interest coverage-3.69x
Cash quality & payout
Operating cash flow / net income0.27x
Accruals ratio-18.6%
Payout ratio—
Capex / revenue2.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: CAD | FY20262026-03-31 | FY20252025-03-31 |
|---|---|---|
| Income statement | ||
| Revenue | 284.60M | 269.00M |
| Cost of revenue | 214.93M | 189.48M |
| Gross profit | 69.67M | 79.51M |
| R&D expense | 2.61M | 2.74M |
| SG&A expense | 159.98M | 169.63M |
| Operating income | -161.66M | -117.14M |
| Interest expense | 38.19M | 74.57M |
| Pretax income | -262.88M | -507.76M |
| Income tax | 23,000 | 7.14M |
| Net income | -262.91M | -508.88M |
| EBITDA | -142.63M | -95.62M |
| EPS (basic) | -0.88 | -4.73 |
| EPS (diluted) | -0.88 | -4.73 |
| Weighted avg. shares (diluted) | 298.04M | 107.55M |
| Balance sheet | ||
| Cash & equivalents | 364.68M | 113.81M |
| Short-term investments | 0 | 17.66M |
| Receivables | 31.24M | 47.51M |
| Inventory | 110.51M | 96.37M |
| Current assets | 529.47M | 294.57M |
| PP&E, net | 316.49M | 293.52M |
| Goodwill | 55.69M | 46.04M |
| Intangibles | 92.41M | 87.20M |
| Total assets | 1.12B | 917.70M |
| Current liabilities | 158.44M | 103.05M |
| Short-term debt | 16.24M | 4.26M |
| Long-term debt | 217.12M | 299.81M |
| Total debt | 233.36M | 304.07M |
| Total liabilities | 421.14M | 439.13M |
| Shareholders' equity | 697.59M | 478.57M |
| Net debt | -131.32M | 190.26M |
| Shares outstanding | 422.07M | 183.87M |
| Cash flow statement | ||
| Operating cash flow | -63.81M | -165.75M |
| Capital expenditure | 5.33M | 10.81M |
| Free cash flow | -69.14M | -176.56M |
| Investing cash flow | -21.35M | -47.79M |
| Financing cash flow | 332.41M | 148.66M |
| Depreciation & amortization | 19.03M | 21.52M |
| Stock-based compensation | 4.27M | -4.21M |
Free plan shows the latest 2 periods; Pro shows all 11 🔒
· Amounts are in the company's reporting currency, CAD, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.